Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
EIT Health’s Innovation Validation Call 2027 supports innovative digital and AI–powered medical technologies that are ready for real-world clinical validation and are approaching market launch. This call addresses the funding gap for solutions that need to run clinical studies and collect evidence to demonstrate safety and efficacy, apply for regulatory approval and prepare for market commercialisation.
The Innovation Validation Call invites organisations from across the Knowledge Triangle (Industry, Education and Research) to submit applications for funding for collaborative projects focused on patient-centric digital health solutions starting at Innovation Maturity Level (IML) 6 – Solution Validation.These innovations are typically at the stage of running pivotal clinical trials and generating real-world evidence that will be instrumental for the market authorisation (e.g. obtaining the CE mark or equivalent) and building commercial readiness of the solution. Solutions must go beyond the state-of-the-art and leverage digital and AI technology to address a critical, unmet healthcare need. They should deliver tangible health outcomes to patients across one or more stages of the patient care pathway, whether through screening, diagnosis, treatment and/or monitoring. Solutions must meet the definition of a Digital medical devices or in-vitro diagnostics device
as defined in the European regulations MDR 2017/745 and IVDR 2017/746.
EIT Health’s Innovation Validation Call is specifically designed to bridge the late-stage valley of death and accelerate the clinical validation of promising digital- and AI-powered healthcare innovations such as digital medical devices and diagnostic solutions.
EIT Health will co-fund collaborative consortium projects aiming to accelerate the clinical validation and market launch of patient-centric digital-and AI-powered health by supporting the following key activities:
The solution must be at an Innovation Maturity Level (IML) of 6 (Initial Clinical Trials), with the aim to reach IML 7 (Solution Validation) by the end of the project.
EIT Health will fund up to 50% of the total project budget, up to a total grant funding amount of €850.000 per project. The commercialising entity must sign a Financial Sustainability Contribution Agreement and, in the case that it is a micro or small enterprise, must receive €400.000 – €500.000 of the grant.
Up to 6 projects may be awarded, subject to the quality of the proposals.
Eligible costs must follow those as set out in the Horizon Europe model grant agreement.
Solutions must have the potential to impact 150.000 EU patients/citizens.
In accordance with the Horizon Europe Work Programme, to be eligible for funding, the applicant must be established in one of the eligible countries, i.e.:
Consortium composition
Consortia of at least two organisations from different countries representing at least two sides of the Knowledge Triangle (industry, research, education). A commercialising company must lead the project. Eligible solutions must be digital or AI-enabled medical devices (MDR/IVDR) at Innovation Maturity Level (IML) 6, aiming to reach IML 7 by project end.
Please refer to EIT Health’s Healthcare Innovation Cycle Framework for more information on the required Innovation Maturity Level for this call.
EIT Community RIS Hub Cyprus
Dr. Styliani Petroudi
EIT Community Officer Cyprus
Email: cyprus@eitcommunity.eu
For general administrative queries, questions about the application platform, or technical issues with the submission process, please contact the EIT Health directly:
via email: calls@eithealth.eu – please include the call code: INNO_VALIDATION27 and your application reference code in the subject line of all correspondence.